Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation filings document a biotechnology royalty aggregator with Nasdaq-listed common stock, Series A cumulative perpetual preferred stock, and Series B depositary shares. Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, completed acquisition activity, and officer appointments tied to the company’s royalty aggregation strategy.
Proxy materials describe annual meeting procedures, board and stockholder voting matters, and governance disclosures. The filing record also documents the company’s capital structure, including preferred stock classes, and formal disclosures around completed acquisitions and related legacy asset information.
Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.
XOMA Royalty Corporation (XOMAP) entered into a merger with HilleVax, Inc. under an Agreement and Plan of Merger dated August 4, 2025, after a related tender offer described in an Offer to Purchase dated August 18, 2025. At the Effective Time, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of XOMA, with outstanding HilleVax shares (subject to customary exceptions) cancelled and converted into the right to receive the Offer Price, comprised of a cash amount and a non-transferable Contingent Value Right (CVR).
A Contingent Value Rights Agreement dated September 17, 2025 governs potential cash payments under the CVR, with Broadridge named as rights agent and Dr. Robert Hershberg as initial representative of holders. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.